

CrossMark
click for updates

Korean J Pediatr

Management issues of congenital adrenal hyperplasia during the transition from pediatric to adult care

Jin-Ho Choi, MD, PhD, Han-Wook Yoo, MD, PhD

Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Steroid 21-hydroxylase deficiency is the most prevalent form of congenital adrenal hyperplasia (CAH), accounting for approximately 95% of cases. With the advent of newborn screening and hormone replacement therapy, most children with CAH survive into adulthood. Adolescents and adults with CAH experience a number of complications, including short stature, obesity, infertility, tumor, osteoporosis, and reduced quality of life. Transition from pediatric to adult care and management of long-term complications are challenging for both patients and health-care providers. Psychosocial issues frequently affect adherence to glucocorticoid treatment. Therefore, the safe transition of adolescents to adult care requires regular follow-up of patients by a multidisciplinary team including pediatric and adult endocrinologists. The major goals for management of adults with 21-hydroxylase deficiency are to minimize the long-term complications of glucocorticoid therapy, reduce hyperandrogenism, prevent adrenal or testicular adrenal rest tumors, maintain fertility, and improve quality of life. Optimized medical or surgical treatment strategies should be developed through coordinated care, both during transition periods and throughout patients' lifetimes. This review will summarize current knowledge on the management of adults with CAH, and suggested appropriate approaches to the transition from pediatric to adult care.

Key words: Adult, Congenital adrenal hyperplasia, 21-Hydroxylase deficiency

Introduction

Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive diseases caused by disorders in adrenal steroidogenesis¹. Steroid 21-hydroxylase deficiency is the most common form of CAH, accounting for approximately 95% of cases². Morbidities associated with CAH include adrenal insufficiency, genital ambiguity in females, and variable degrees of postnatal androgen excess². With the advent of newborn screening and hormone replacement therapy, most children with CAH survive into adulthood. As a result, individuals with CAH who reach adolescence and adulthood can develop from several long-term complications, including short stature, precocious puberty, obesity, hypertension, polycystic ovary syndrome, infertility, tumor, osteoporosis, and reduced quality of life²⁻⁴.

Management of CAH during adolescence and the transition from pediatric to adult care are challenging tasks because hormonal changes during puberty can lead to inadequate suppression of adrenal androgens³. In addition, psychosocial status affects adherence to medication in adolescence and young adulthood⁴. Therefore, treatment regimens should be reassessed during adolescence and adulthood. Successful transition from pediatric to adult care requires regular follow-up of patients by a multidisciplinary team including pediatric

Corresponding author: Jin-Ho Choi, MD, PhD
Department of Pediatrics, Asan Medical Center
Children's Hospital, University of Ulsan College of
Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul
05505, Korea
Tel: +82-2-3010-3991
Fax: +82-2-473-3725
E-mail: jhc@amc.seoul.kr

Received: 20 November, 2015

Revised: 21 January, 2016

Accepted: 13 February, 2016

Copyright © 2017 by The Korean Pediatric Society

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

endocrinologists, urologists, gynecologists, psychiatrists, and adult endocrinologists. The transition process should be prepared and planned gradually in order to empower the adolescent to assume greater responsibility for their own health-care³. Thus, thorough education of patients and health-care providers is critical for successful transition from pediatric to adult care.

The major treatment goals during transition from pediatric to adult care are to minimize the long-term complications of glucocorticoid therapy, to reduce adrenal hyperandrogenism, to prevent adrenal or testicular adrenal rest tumors (TARTs), to maintain fertility, and to optimize quality of life³. New medical and surgical treatment strategies, transition protocols, and coordinated care systems are being developed to improve the long-term outcomes of adults with CAH³. However, it is imperative that health-care providers perform further research to investigate the natural history of CAH in adults, and to establish optimal interventions for effective transition programs that will improve treatment outcomes.

This review describes current knowledge regarding the long-term consequences of CAH in adolescence and adulthood and management issues during the transition period from child to adult care.

Hormonal changes in patients with 21-hydroxylase deficiency during puberty

Profound hormonal changes occur during the transition from childhood to adulthood. Pubertal activation of the hypothalamic-pituitary-gonadal axis and increases in growth hormone and insulin-like growth factor 1 secretion have been shown to decrease 11 β -hydroxysteroid dehydrogenase type 1 activity and increase glomerular filtration rate, resulting in increased cortisol

clearance^{4,5}. These changes can decrease the effectiveness of glucocorticoid drugs. In addition, age-related physiological increases in adrenal androgens and insulin resistance are amplified in adolescents with 21-hydroxylase deficiency, which can complicate management of the condition⁴.

Long-term consequences of 21-hydroxylase deficiency in adolescents and adults

Adolescents and adults with 21-hydroxylase deficiency can experience long-term complications such as short stature, precocious puberty, obesity, hypertension, hirsutism, polycystic ovary syndrome, adrenal or testicular tumors, infertility, and osteoporosis^{3,6}.

Linear growth is initially accelerated in children with CAH; however, final adult height is reported as one to 2 standard deviations below the mean for patients' target heights (Table 1)⁷. Inadequately treated patients may not reach their potential target height because adrenal androgens cause premature epiphyseal fusion. Overtreatment with glucocorticoids is also strongly associated with poor height outcomes⁸. Therefore, it is important to use the lowest possible glucocorticoid doses in order to optimize final adult height⁸.

Obesity is common in patients with CAH, and children with 21-hydroxylase deficiency have a high body mass index (BMI) throughout childhood and adulthood (Table 1)⁹. These data suggest that many patients with 21-hydroxylase deficiency are overtreated¹⁰. In previous reports, children with CAH had a higher BMI in 16%–25% of cases^{11,12}. In addition, hypertension is prevalent in children and adolescents with CAH and has been related to BMI independent of glucocorticoid or mineralocorticoid therapy¹³. Lifestyle interventions are recommended to prevent the

Table 1. Auxological characteristics of adults with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency

Reference	No.	Sex	FAH SDS	MPH SDS	FAH-MPH SDS	Body mass index SDS
Eugster et al. ⁷ (2001)	65	All	-1.04	-0.009	-1.03	NA
Hargitai et al. ⁴⁷ (2001)	40	Male	-1.55	NA	NA	NA
	84	Female	-1.23			
Muirhead et al. ⁴⁸ (2002)	23	Male	-1.4	NA	-1.1	NA
	31	Female	-0.9		-1.1	
Pinto et al. ⁴⁹ (2003)	2	Male	-2.2	NA	NA	-1.8
	14	Female	-1.8±0.3*			-1.4±0.5*
Vöikl et al. ¹¹ (2006)	41	Male	NA	NA	NA	1.03±1.31*
	48	Female				0.75±1.37*
Nermoen et al. ⁵⁰ (2012)	23	Male	168.2±7.6*	NA	NA	27.8±4.9 [§]
	41	Female	159.1±7.1*			28.0±8.6 ^{*§}
Bouvattier et al. ²⁹ (2015)	211	All	167.8 (144–190) [†]	NA	NA	26.5±5.6 (17.8–2.5) ^{‡§}

FAH, final adult height; MPH, midparental height; NA, not available; SDS, standard deviation score.

*Mean±standard deviation. [†]Median (range). [‡]Mean±SD (range). [§]kg/m².

potential metabolic consequences of obesity².

Common tumors in adults with 21-hydroxylase deficiency include TARTs and tumors of the adrenal cortex. Adrenal masses occur in 1%–4% of general population¹⁴. High prevalence of adrenal tumors has been observed in adults with CAH, especially among those with inadequate glucocorticoid therapy¹⁵. The enlargement of the adrenal glands in 21-hydroxylase deficiency predisposes sufferers to adrenal tumors, including myelolipomas¹⁶. Myelolipomas are commonly found in patients with 21-hydroxylase deficiency and can be enormous, requiring removal for mass effect¹⁶. However, it is recommended that adrenal imaging is reserved for patients manifesting atypical clinical courses or biochemical findings².

TARTs are one of the most common complications in male CAH patients with insufficient glucocorticoid replacement therapy⁶. Around 30%–50% of men with 21-hydroxylase deficiency develop TARTs¹⁷. These TARTs are benign and decrease in size after high doses of glucocorticoid therapy^{18,19}. If TARTs are unresponsive to glucocorticoid therapy, surgical intervention using a testis-sparing procedure and cryopreservation of the semen may be necessary^{17,20}. It has been recommended that periodic ultrasonography is performed to evaluate TARTs during follow-up of males with CAH².

CAH has implications for reproductive functions such as menstruation and fertility. Irregular menstrual cycles commonly occur in females with CAH who receive inadequate treatment²¹. Females with poorly-controlled classic CAH can also experience hirsutism, oligomenorrhea, amenorrhea, menorrhagia, and acne; a collection of symptoms often observed in polycystic ovary syndrome⁸. Functional ovarian hyperandrogenism can cause irregular menstruation even in women with well-controlled CAH²². However, routine pelvic ultrasonography is not required for females with CAH who have regular menstrual cycles².

Impaired fertility is reported in both males and females with 21-hydroxylase deficiency. Affected women experience a number of impediments to fertility, including vaginal insufficiency with dyspareunia, anovulation, and polycystic ovary syndrome caused by elevated adrenal androgens³. Reduced fertility is especially common among those with salt-losing forms of CAH^{20,23} due to high adrenal androgen levels that lead to anovulatory cycles²⁴, and incomplete surgical reconstruction impairing sexual intercourse²⁵. Fertility rates in simple virilizing CAH have been reported to be around 50%²³. In women with nonclassic CAH, a retrospective multicenter review demonstrated that 68% of 101 women had become pregnant before the diagnosis was made, implying that glucocorticoid treatment is not essential for fertility²⁶. In males with 21-hydroxylase deficiency, the mechanism of impaired fertility is gonadotropin suppression by adrenal androgens when adequate doses of glucocorticoids are not administered, which results in testicular atrophy impairing spermatogene-

sis^{27,28}. In addition, the development of TARTs cause obstruction of the seminiferous tubules and the normal testis tissue, leading to impaired blood flow, functional impairment, and fibrosis³. In a large cohort study, TARTs were found in 34% of patients, and severe oligospermia and azospermia were prevalent in 70% of these cases²⁹.

A major complications of long-term glucocorticoid treatment is osteoporosis. Glucocorticoid therapy inhibits osteoblastic activity, leading to decreased bone mineral density³⁰. Reduced bone mineral density has been inversely correlated with cumulative doses of glucocorticoid³¹. A retrospective study of 62 adult women with CAH found that overtreatment with glucocorticoids lead to osteoporosis, along with an increased incidence of fractures³². However, routine bone mineral densitometry is not recommended because there is no evidence of an increased incidence of osteoporosis among adults with CAH who do not receive overtreatment^{33,34}. Further studies into longitudinal follow-up of bone mineral density would be useful to investigate the occurrence of osteoporosis in adult patients with 21-hydroxylase deficiency².

Assessment of adolescents and adults during transition from pediatric care

Prevention and management of long-term complications, and maintaining quality of life is a major concern for adolescents and adults with 21-hydroxylase deficiency³. Patient medical histories and physical signs of overtreatment or undertreatment for CAH should be considered. This could include reviewing past treatment regimens, frequency of adrenal crises, adherence to medication, regular menstruation, cushinoid features, skin hyperpigmentation, and testicular size³. Extensive education of patients and coordination of services among health-care providers for adults with 21-hydroxylase deficiency remains a major task during the transition from pediatric to adult care³⁵. The patient's knowledge of the disease should be evaluated, as well as understanding of stress dose of glucocorticoids and emergency use of hydrocortisone³.

Medical treatment of adolescents and adults with 21-hydroxylase deficiency

In children with CAH, glucocorticoid doses should be adjusted to prevent hyperandrogenism and optimize growth. Glucocorticoid must be given in doses sufficient to suppress adrenal androgen secretion, without total suppression of the hypothalamic-pituitary-adrenal axis². The recommended dose of hydrocortisone

for growing children is 10–15 mg/m²/day²). In adults with CAH whose growth and development are complete, the goal of treatment is to prevent long-term complications, to preserve fertility and satisfactory sexual function, and to maintain general well-being and physical performance⁶. Pediatric doses of glucocorticoids should be reassessed during the transition to adult care in order to avoid overtreatment. High dose glucocorticoid therapy can lead to cushinoid features, short stature, weight gain, hypertension, hirsutism, infertility, osteoporosis, and impaired glucose tolerance⁶, while excess mineralocorticoids may result in hypertension². Adults with classic CAH are treated with physiologic doses of hydrocortisone to prevent adrenal insufficiency; however, this does not suppress adrenocorticotrophic hormone and adrenal androgen production. Inadequate androgen suppression in CAH can result in short stature, early puberty, virilization in females, infertility, adrenal tumors, TARTs in males, and adverse psychological sequelae⁴. As a result of these factors, it is difficult to suppress adrenal androgen secretion without overtreatment with glucocorticoid, and patients often experience hypercortisolism, androgen excess, or a combination of these states (Fig. 1)⁹.

Hydrocortisone (15–25 mg/day) is the first line of therapy for 21-hydroxylase deficiency. However, 3 times daily medication is required due to its short half-life, and this can lead to poor treatment adherence³. The second line of therapy is to add a small bedtime dose of a long-acting glucocorticoids, such as prednisolone (1–2 mg) or dexamethasone (0.1–0.5 mg)³. If this regimen is insufficient to achieve control of the condition, or represents too many doses during the day, twice daily prednisolone (4–6 mg/day) is the third alternative². The fourth line of treatment consists of once or twice daily dexamethasone (0.25–0.5 mg/day), although this should be used cautiously because of the associated complications, such as iatrogenic Cushing syndrome³.




Fig. 1. Balance between overtreatment and undertreatment in the management of adults with 21-hydroxylase deficiency. If a glucocorticoid is administered at physiologic dose to prevent adrenal insufficiency, hyperandrogenism persists. However, if the glucocorticoid dose is increased to suppress excess adrenal androgen, hypercortisolism can occur. SDS, standard deviation score; BP, blood pressure; GC, glucocorticoid.

The need for mineralocorticoids decreases with age, because levels of serum aldosterone are high and renal mineralocorticoid receptor mRNA are low at birth³⁶. Doses of fludrocortisone can be substantially reduced in adults, and may no longer be required in some patients, even those with salt-losing forms of CAH³⁷. However, optimal dosage of fludrocortisone in adults has not been studied, and the adequacy of mineralocorticoid supplementation must be monitored by observing blood pressure and plasma renin activity².

Laboratory testing and monitoring of adolescents and adults with 21-hydroxylase deficiency

Regular appropriate hormone measurements should be taken during the transition from pediatric to adult care. Serum 17 α -hydroxyprogesterone (17-OHP) is the standard for diagnosis and a sensitive parameter for assessing disease control; however, correlation of 17-OHP with androgen levels in adults is highly variable³. Levels of sex hormone binding globulin and total testosterone levels can be used to assess to calculate free testosterone in women with 21-hydroxylase deficiency³. Follicular-phase serum progesterone levels should be assessed in women with chronic amenorrhea and be maintained below 0.6 ng/mL³⁸. In males with 21-hydroxylase deficiency, androstenedione and gonadotropin levels should be checked in order to monitor adrenal androgens and testicular function³. Periodic screening for TARTs by testicular ultrasonography is also necessary from adolescence onward².

Treatment of adults with nonclassic CAH

In cases where enzyme activity is preserved to a certain degree, patients with 21-hydroxylase deficiency remain asymptomatic until puberty⁶. Most patients with the nonclassic form present with hirsutism or menstrual irregularities at the time of puberty or early adolescence⁶. Asymptomatic adults do not require daily glucocorticoid treatment. However, it is recommended that children with inappropriately early onset and rapid progression of pubarche and adolescents with overt virilization should be treated².

Management of women with 21-hydroxylase deficiency during pregnancy

For pregnant women who experience difficulties due to vaginal stenosis or dyspareunia, vaginal reconstruction surgery can be performed. However, some women suffer bladder infections or

abscesses, cysts, or scar tissue³⁵). Women with CAH should be managed by both endocrinologists and obstetricians during pregnancy². Pregnant women with 21-hydroxylase deficiency should be treated with hydrocortisone or prednisolone^{2,39}. Dexamethasone should not be used to treat the pregnant woman with CAH because it is not inactivated by placental 11 β -hydroxysteroid dehydrogenase type 2, and thus can suppress the fetal adrenal glands and cause low birth weight^{2,40}. In some cases, slightly higher doses of glucocorticoid may be needed to induce ovulation. In such cases, serum progesterone levels should be maintained below 0.6 ng/mL³⁸. In the third trimester of pregnancy, glucocorticoid dose may be increased up to 50%³⁷. During labor and delivery, stress doses of glucocorticoids should be administered; however, there are no controlled studies or guidelines regarding optimal doses of glucocorticoids at this point².

Psychological support and counseling

Exposure to excess androgens during the prenatal period influences brain development of females with classic CAH⁴¹. Females with classic CAH may display more sexual concerns and masculine behavior than unaffected females⁴²⁻⁴⁴. They are less likely to have sexual relations than females in control groups, and those with the salt-losing form have poorer psychosocial functioning⁴⁵. Although gender-atypical behavior has been reported, women with CAH frequently identify themselves as female and reversal of gender identity is extremely rare^{41,44}. In contrast, severely virilized females may be raised as males initially, and once such an assignment made, it can be difficult to reverse gender identity².

There is a lack of guidelines regarding psychosexual management of patients with CAH. Patients may have psychosocial problems associated with disorders of sexual development and need specialized care by psychiatrists with expertise in such problems². Multidisciplinary guidance in the area of psychosexual function is critical with regards to gender identity or dysphoria⁶.

Multidisciplinary team approach during transition period

Unfortunately, a considerable number of CAH patients are lost to regular follow-up once they move out of pediatric care⁶. This is likely the result of inadequate cooperation between pediatric and adult endocrinologists at the time of transition to adult care. This transition should be processed gradually⁴⁶, therefore, it is recommended that pediatric endocrinologists, gynecologists, urologists, psychiatrist, and adult endocrinologists perform joint clinics for transferring CAH patients to adult care². Adults with

21-hydroxylase deficiency require careful screening for tumors, osteoporosis, obesity, and maintenance of general health³⁵. The approach to adults with 21-hydroxylase deficiency requires detailed information on the patient's prior treatment, the natural history and long-term consequences of the disease, and the influence of various treatments on adrenal and gonadal steroidogenesis. Therefore, it would be desirable to have adult endocrinologists with special expertise in the treatment of CAH patients⁶.

Conclusions

Patients with CAH must experience a transition from pediatric to adult care, and can develop various long-term complications. Transition of adolescents to adult care involves changes in treatment goals toward prevention of long-term complications and optimization of quality of life. Careful monitoring, extensive education, and follow-up should be required for patients with CAH, with greater vigilance in the monitoring of biochemical and clinical features. Optimal treatment of adults with 21-hydroxylase deficiency can be achieved through a multidisciplinary approach, including consultation with pediatric and adult endocrinologists. Further investigations are needed to investigate the natural history of CAH and to develop management guidelines for adolescents and adults with 21-hydroxylase deficiency.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Speiser PW, White PC. Congenital adrenal hyperplasia. *N Engl J Med* 2003;349:776-88.
2. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2010;95:4133-60.
3. Auchus RJ. Management considerations for the adult with congenital adrenal hyperplasia. *Mol Cell Endocrinol* 2015;408:190-7.
4. Merke DP, Poppas DP. Management of adolescents with congenital adrenal hyperplasia. *Lancet Diabetes Endocrinol* 2013;1:341-52.
5. Charmandari E, Brook CG, Hindmarsh PC. Classic congenital adrenal hyperplasia and puberty. *Eur J Endocrinol* 2004;151 Suppl 3:U77-82.
6. Kruse B, Riepe FG, Krone N, Bosinski HA, Kloehn S, Partsch CJ, et al. Congenital adrenal hyperplasia - how to improve the transition from adolescence to adult life. *Exp Clin Endocrinol Diabetes* 2004;112:343-55.
7. Eugster EA, Dimeglio LA, Wright JC, Freidenberg GR, Seshadri R,

- Pescovitz OH. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. *J Pediatr* 2001;138:26-32.
8. White PC, Speiser PW. Long-term consequences of childhood-onset congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab* 2002;16:273-88.
 9. Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2008;93:653-60.
 10. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. *J Clin Endocrinol Metab* 2010;95:5110-21.
 11. Völkl TM, Simm D, Beier C, Dörr HG. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Pediatrics* 2006;117:e98-105.
 12. Völkl TM, Simm D, Körner A, Rascher W, Kiess W, Kratzsch J, et al. Does an altered leptin axis play a role in obesity among children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency? *Eur J Endocrinol* 2009;160:239-47.
 13. Völkl TM, Simm D, Dötsch J, Rascher W, Dörr HG. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2006;91:4888-95.
 14. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. *Eur J Endocrinol* 2003;149:273-85.
 15. Jaresch S, Kornely E, Kley HK, Schlaghecke R. Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1992;74: 685-9.
 16. Nermoen I, Rørvik J, Holmedal SH, Hykkerud DL, Fougner KJ, Svartberg J, et al. High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. *Clin Endocrinol (Oxf)* 2011;75:753-9.
 17. Claahsen-van der Grinten HL, Otten BJ, Hermus AR, Sweep FC, Hulsbergen-van de Kaa CA. Testicular adrenal rest tumors in patients with congenital adrenal hyperplasia can cause severe testicular damage. *Fertil Steril* 2008;89:597-601.
 18. Stikkelbroeck NM, Hermus AR, Suliman HM, Jager GJ, Otten BJ. Asymptomatic testicular adrenal rest tumours in adolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. *J Pediatr Endocrinol Metab* 2004;17:645-53.
 19. Jin HY, Choi JH, Kim GH, Lee CS, Yoo HW. Testicular adrenal rest tumors in a patient with untreated congenital adrenal hyperplasia. *Korean J Pediatr* 2011;54:137-40.
 20. Claahsen-van der Grinten HL, Stikkelbroeck NM, Sweep CG, Hermus AR, Otten BJ. Fertility in patients with congenital adrenal hyperplasia. *J Pediatr Endocrinol Metab* 2006;19:677-85.
 21. Holmes-Walker DJ, Conway GS, Honour JW, Rumsby G, Jacobs HS. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Clin Endocrinol (Oxf)* 1995;43:291-6.
 22. Barnes RB, Rosenfield RL, Ehrmann DA, Cara JF, Cuttler L, Levitsky LL, et al. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. *J Clin Endocrinol Metab* 1994;79:1328-33.
 23. Stikkelbroeck NM, Beerendonk CC, Willemsen WN, Schreuders-Bais CA, Feitz WF, Rieu PN, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. *J Pediatr Adolesc Gynecol* 2003;16:289-96.
 24. Premawardhana LD, Hughes IA, Read GF, Scanlon MF. Longer term outcome in females with congenital adrenal hyperplasia (CAH): the Cardiff experience. *Clin Endocrinol (Oxf)* 1997;46:327-32.
 25. Alizai NK, Thomas DF, Lilford RJ, Batchelor AG, Johnson N. Feminizing genitoplasty for congenital adrenal hyperplasia: what happens at puberty? *J Urol* 1999;161:1588-91.
 26. Bidet M, Bellanné-Chantelot C, Galand-Portier MB, Golmard JL, Tardy V, Morel Y, et al. Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2010;95:1182-90.
 27. Tiitinen A, Välimäki M. Primary infertility in 45-year-old man with untreated 21-hydroxylase deficiency: successful outcome with glucocorticoid therapy. *J Clin Endocrinol Metab* 2002;87:2442-5.
 28. Reisch N, Flade L, Scherr M, Rottenkolber M, Pedrosa Gil F, Bidlingmaier M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2009;94:1665-70.
 29. Bouvattier C, Esterle L, Renoult-Pierre P, de la Perrière AB, Illouz F, Kerlan V, et al. Clinical outcome, hormonal status, gonadotrope axis, and testicular function in 219 adult men born with classic 21-hydroxylase deficiency. A French National Survey. *J Clin Endocrinol Metab* 2015;100:2303-13.
 30. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. *J Intern Med* 1995;237:439-47.
 31. Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. *Eur J Endocrinol* 2008;158:879-87.
 32. Falhammar H, Filipsson H, Holmdahl G, Janson PO, Nordenskjöld A, Hagenfeldt K, et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2007;92:4643-9.
 33. Girgis R, Winter JS. The effects of glucocorticoid replacement therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 1997;82:3926-9.
 34. Gussinyé M, Carrascosa A, Potau N, Enrubia M, Vicens-Calvet E, Ibáñez L, et al. Bone mineral density in prepubertal and in adolescent and young adult patients with the salt-wasting form of congenital adrenal hyperplasia. *Pediatrics* 1997;100:671-4.
 35. Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2013;98:2645-55.
 36. Martinierie L, Viengchareun S, Delezoide AL, Jaubert F, Sinico M, Prevot S, et al. Low renal mineralocorticoid receptor expression at birth contributes to partial aldosterone resistance in neonates. *Endocrinology* 2009;150:4414-24.
 37. Reisch N. Substitution therapy in adult patients with congenital adrenal hyperplasia. *Best Pract Res Clin Endocrinol Metab* 2015;29:33-45.
 38. Casteràs A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. *Clin Endocrinol (Oxf)* 2009;70:833-7.
 39. Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. *Endocrinol Metab Clin North*

- Am 2001;30:207-29.
40. Ogilvie CM, Crouch NS, Rumsby G, Creighton SM, Liao LM, Conway GS. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. *Clin Endocrinol (Oxf)* 2006;64:2-11.
 41. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Prenatal androgenization affects gender-related behavior but not gender identity in 5-12-year-old girls with congenital adrenal hyperplasia. *Arch Sex Behav* 2004;33:97-104.
 42. Berenbaum SA, Duck SC, Bryk K. Behavioral effects of prenatal versus postnatal androgen excess in children with 21-hydroxylase-deficient congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2000;85:727-33.
 43. Berenbaum SA. Cognitive function in congenital adrenal hyperplasia. *Endocrinol Metab Clin North Am* 2001;30:173-92.
 44. Berenbaum SA, Bailey JM. Effects on gender identity of prenatal androgens and genital appearance: evidence from girls with congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2003;88:1102-6.
 45. Gastaud F, Bouvattier C, Duranteau L, Brauner R, Thibaud E, Kutten F, et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. *J Clin Endocrinol Metab* 2007;92:1391-6.
 46. Auchus RJ, Witchel SF, Leight KR, Aisenberg J, Azziz R, Bachega TA, et al. Guidelines for the Development of comprehensive care centers for congenital adrenal hyperplasia: guidance from the CARES foundation initiative. *Int J Pediatr Endocrinol* 2010;2010:275213.
 47. Hargitai G, Sólyom J, Battelino T, Lebl J, Pribilincová Z, Hauspie R, et al. Growth patterns and final height in congenital adrenal hyperplasia due to classical 21-hydroxylase deficiency. Results of a multicenter study. *Horm Res* 2001;55:161-71.
 48. Muirhead S, Sellers EA, Guyda H; Canadian Pediatric Endocrine Group. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. *J Pediatr* 2002;141:247-52.
 49. Pinto G, Tardy V, Trivin C, Thalassinos C, Lortat-Jacob S, Nihoul-Fékété C, et al. Follow-up of 68 children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: relevance of genotype for management. *J Clin Endocrinol Metab* 2003;88:2624-33.
 50. Nerموen I, Brønstad I, Fougner KJ, Svartberg J, Øksnes M, Husebye ES, et al. Genetic, anthropometric and metabolic features of adult Norwegian patients with 21-hydroxylase deficiency. *Eur J Endocrinol* 2012;167:507-16.